Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105183 · ClinicalTrials.gov registry record · Phase 3
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
A Phase 3 study, sponsored by Neovii Biotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 223
- Enrollment target
NCT00105183: Completed Phase 3 study, sponsored by Neovii Biotech.
NCT00105183 is a Phase 3 study that has completed, run by Neovii Biotech. The registered enrollment target is 223 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00105183, a Phase 3 study, has completed, sponsored by Neovii Biotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 223 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or lungs.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL EZ-2053
- BIOLOGICAL EZ-2053 5mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2005-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
What the finished NCT00105183 record still lists
NCT00105183 is an interventional study that assigns participants to a tested intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00105183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00105183 about?
NCT00105183 is a clinical study titled "EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection". The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or lungs.
What is the current status of trial NCT00105183?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 223 participants. The study started on 2005-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00105183?
The interventions under investigation include: Placebo (BIOLOGICAL), EZ-2053 (BIOLOGICAL), EZ-2053 5mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00105183?
This trial is sponsored by Neovii Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00105183's enrollment target sits among peer trials
223 1317th of 2000 higher than 684 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06640803 · 223 participants · NA
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
- NCT07175285 · 223 participants
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- NCT07205718 · 223 participants · Phase 1
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia